| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Interleukin-25, IL-25, Interleukin-17E, IL-17E, IL25, IL17E |
| Entrez GeneID | 64806 |
| WB Predicted band size | 20.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This IL25 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 76-104 amino acids from the Central region of human IL25. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于IL25抗体的3篇参考文献示例(注：文献信息为模拟生成，实际引用请核实数据库)：
---
1. **标题**：Anti-IL25 Antibody Therapy Attenuates Airway Inflammation in a Murine Asthma Model
**作者**：Chen Y, Wang L, et al.
**摘要**：研究通过在小鼠哮喘模型中注射IL25中和抗体，发现其能显著减少肺部嗜酸性粒细胞浸润和Th2细胞因子(如IL-4、IL-5)水平，表明靶向IL25可能成为过敏性哮喘的潜在治疗策略。
---
2. **标题**：Blockade of IL-25 Signaling Enhances Antitumor Immunity in Colorectal Cancer
**作者**：Smith J, Patel R, et al.
**摘要**：该文献报道IL25抗体通过抑制肿瘤微环境中ILC2细胞的活化，增强CD8+ T细胞抗肿瘤活性，从而抑制结直肠癌小鼠模型的肿瘤生长，提示IL25靶向治疗在癌症免疫治疗中的应用潜力。
---
3. **标题**：IL-25 Neutralization Reduces Skin Inflammation in Atopic Dermatitis
**作者**：Zhang H, Kim S, et al.
**摘要**：在特应性皮炎小鼠模型中，IL25抗体治疗显著缓解了皮肤红斑、水肿及Th2相关炎症反应，表明IL25在介导皮肤屏障功能障碍中的关键作用及抗体干预的有效性。
---
如需具体文献，建议在PubMed或Web of Science中搜索关键词“IL25 antibody”或“anti-IL25 therapy”获取最新研究。
Interleukin-25 (IL-25), also known as IL-17E, is a cytokine belonging to the IL-17 family. Unlike other IL-17 members, IL-25 primarily regulates type 2 immune responses, playing a critical role in allergic inflammation, parasitic infections, and tissue repair. It is secreted by epithelial cells, eosinophils, and innate lymphoid cells (ILC2s), and signals through a heterodimeric receptor (IL-17RA/IL-17RB) to activate pathways like NF-κB and STAT5. This induces the production of type 2 cytokines (e.g., IL-4. IL-5. IL-13), promoting eosinophil recruitment, mucus production, and anti-helminth immunity. However, dysregulated IL-25 is implicated in chronic inflammatory diseases, including asthma, atopic dermatitis, and inflammatory bowel disease.
IL-25 antibodies are therapeutic agents designed to neutralize IL-25 activity, thereby suppressing pathological type 2 inflammation. These monoclonal antibodies (mAbs) typically target IL-25 or its receptor subunits, blocking ligand-receptor interactions. Preclinical studies in animal models demonstrate reduced inflammation and improved disease outcomes in asthma and fibrosis. Several candidates are in early-stage clinical trials, though challenges remain, such as balancing therapeutic efficacy with potential immunosuppressive risks (e.g., impaired tissue repair or defense against parasites). Research also explores combination therapies with other biologics targeting the IL-17 or Th2 pathways. IL-25 antibodies represent a promising strategy for diseases driven by excessive type 2 immunity, but their long-term safety and precise mechanisms require further investigation.
×
